Form 4 holding
Director
BIOCRYST PHARMACEUTICALS INC
- Security class
- Common Stock
- Shares / value
- 99,138
- Estimated value
- $1,025,086
- Report date
- 12 Jun 2025
- Price
- $10.34
- Ownership
- Direct
Nancy J. Hutson
Insider Reports History
- Reporting-owner location
- Stonington, CT
- Latest reporting-owner signature
-
/s/ Alane P. Barnes, by power of attorney
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
Identity
Names, identifiers, and filing context for this profile.
1 identity field
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Nancy J. Hutson
Form 4 holding
Director
Endo International plc
- Security class
- Ordinary Shares
- Shares / value
- 116,140
- Estimated value
- $727,036
- Report date
- 11 Jun 2021
- Price
- $6.26
- Ownership
- Direct
Form 4 holding
Director
Clearside Biomedical, Inc.
- Security class
- Common Stock
- Shares / value
- 93,000
- Estimated value
- $118,110
- Report date
- 03 Oct 2023
- Price
- $1.27
- Ownership
- Direct
Form 4 holding
Director
Clearside Biomedical, Inc.
- Security class
- Stock Option (right to buy)
- Shares / value
- 45,000
- Estimated value
- Report date
- 20 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PhaseBio Pharmaceuticals Inc
- Security class
- Common Stock
- Shares / value
- 37,510
- Estimated value
- Report date
- 19 May 2023
- Price
- Ownership
- Direct
Form 4 holding
Director
BIOCRYST PHARMACEUTICALS INC
- Security class
- Automatic Stock Option Grant
- Shares / value
- 27,181
- Estimated value
- Report date
- 12 Jun 2025
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
PhaseBio Pharmaceuticals Inc
- Security class
- Common Stock
- Shares / value
- 4,000
- Estimated value
- Report date
- 19 May 2023
- Price
- Ownership
- Held in an individual retirement account for the benefit of the Reporting Person
Form 4 holding
Director
PhaseBio Pharmaceuticals Inc
- Security class
- Restricted Stock Units
- Shares / value
- 0
- Estimated value
- Report date
- 19 May 2023
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Insider Reports Filed by Nancy J. Hutson
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 12 Jun 2025
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 16 Jun 2025, 16:20
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 13 Dec 2024
- Transactions
- 1
- Transaction value
- -$52,780
- Accepted by SEC
- 16 Dec 2024, 16:35
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 20 Jun 2024
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 21 Jun 2024, 16:15
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 12 Jun 2024
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 14 Jun 2024, 16:27
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 20 May 2024
- Transactions
- 1
- Transaction value
- +$31,900
- Accepted by SEC
- 22 May 2024, 07:24
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 03 Oct 2023
- Transactions
- 1
- Transaction value
- +$8,600
- Accepted by SEC
- 04 Oct 2023, 17:06
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 22 Jun 2023
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 23 Jun 2023, 16:38
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 13 Jun 2023
- Transactions
- 3
- Transaction value
- -$103,443
- Accepted by SEC
- 15 Jun 2023, 16:33
- Role
- Director
- Next action
- Open filing details
4
PhaseBio Pharmaceuticals Inc
- Report period
- 19 May 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 19 May 2023, 16:15
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 17 Nov 2022
- Transactions
- 1
- Transaction value
- +$39,900
- Accepted by SEC
- 21 Nov 2022, 07:12
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 22 Jun 2022
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 24 Jun 2022, 16:25
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 07 Jun 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 09 Jun 2022, 16:48
- Role
- Director
- Next action
- Open filing details
4
PhaseBio Pharmaceuticals Inc
- Report period
- 19 May 2022
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 20 May 2022, 16:45
- Role
- Director
- Next action
- Open filing details
4
PhaseBio Pharmaceuticals Inc
- Report period
- 05 Nov 2021
- Transactions
- 6
- Transaction value
- $0
- Accepted by SEC
- 08 Nov 2021, 17:26
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 29 Oct 2021
- Transactions
- 4
- Transaction value
- +$81,350
- Accepted by SEC
- 02 Nov 2021, 16:40
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 15 Oct 2021
- Transactions
- 9
- Transaction value
- -$1,253,550
- Accepted by SEC
- 19 Oct 2021, 16:21
- Role
- Director
- Next action
- Open filing details
4/A
PhaseBio Pharmaceuticals Inc
- Report period
- 18 Aug 2021
- Transactions
- 1
- Transaction value
- +$9,240
- Accepted by SEC
- 20 May 2022, 16:47
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 16 Aug 2021
- Transactions
- 1
- Transaction value
- +$17,040
- Accepted by SEC
- 17 Aug 2021, 16:39
- Role
- Director
- Next action
- Open filing details
4
Endo International plc
- Report period
- 11 Jun 2021
- Transactions
- 2
- Transaction value
- -$143,999
- Accepted by SEC
- 15 Jun 2021, 16:06
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 10 Jun 2021
- Transactions
- 5
- Transaction value
- -$319,845
- Accepted by SEC
- 14 Jun 2021, 16:29
- Role
- Director
- Next action
- Open filing details
4
CLSD
Clearside Biomedical, Inc.
- Report period
- 10 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 11 Jun 2021, 17:40
- Role
- Director
- Next action
- Open filing details
4
PhaseBio Pharmaceuticals Inc
- Report period
- 03 Jun 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 04 Jun 2021, 18:05
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 28 May 2021
- Transactions
- 1
- Transaction value
- +$4,999
- Accepted by SEC
- 01 Jun 2021, 16:24
- Role
- Director
- Next action
- Open filing details
4
BCRX
BIOCRYST PHARMACEUTICALS INC
- Report period
- 25 May 2021
- Transactions
- 1
- Transaction value
- $0
- Accepted by SEC
- 27 May 2021, 16:24
- Role
- Director
- Next action
- Open filing details